Metraipolis › archive › dc_ae8bd4660144

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab — Europe PMC PMID:41560729

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41560729
DOI
10.3389/fphar.2025.1714173
License (as archived)
solo-consultazione
Archived
2026-11-07T01:47:03.469Z
SHA-256 of the archived text
da8ea89d48e66a12d63632c2059140c566580b78b7dfe2b6426349d30dd89a68
Stable URL of this page
https://metraipolis.com/documento/dc_ae8bd4660144

How to cite

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab — Europe PMC PMID:41560729 — Europe PMC (en), https://europepmc.org/article/MED/41560729 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ae8bd4660144 (Metraipolis archive dc_ae8bd4660144, sha256 da8ea89d48e66a12d63632c2059140c566580b78b7dfe2b6426349d30dd89a68)
BibTeX
@misc{dcae8bd4660144,
  title = {A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab — Europe PMC PMID:41560729},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41560729},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ae8bd4660144; sha256 da8ea89d48e66a12d63632c2059140c566580b78b7dfe2b6426349d30dd89a68},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41560729. Agents can read the archived copy with the MCP tool read_document.